csnk1da Antibody

Introduction to CSNK1D Antibody

The CSNK1D antibody specifically binds to CK1δ, a 47 kDa protein involved in phosphorylation-dependent regulation of signaling pathways, including Wnt/β-catenin, p53, and Hedgehog . CK1δ overexpression or dysregulation is linked to cancers, neurological disorders, and metabolic diseases, making this antibody critical for mechanistic and therapeutic studies .

Key Findings Using CSNK1D Antibodies

• Cancer Research: CK1δ is overexpressed in breast, colorectal, and lung cancers. Antibodies enable detection of CK1δ's role in stabilizing oncoproteins like β-catenin and disrupting tumor suppressors like p53 .

• DNA Damage Response: CK1δ phosphorylates p53 (Ser-9, Ser-20) and UHRF1 (Ser-108), influencing DNA repair and replication under stress .

• Therapeutic Targeting: RNA interference (RNAi) and CRISPR/Cas9 studies utilize CSNK1D antibodies to validate CK1δ knockdown efficacy in preclinical cancer models .

Therapeutic Implications

Inhibiting CK1δ via antibodies or small molecules shows promise in cancer therapy. For example:

• RNAi-Based Approaches: Silencing CSNK1D reduces tumor growth in models of colorectal and breast cancer .

• Combination Therapies: CK1δ inhibitors synergize with chemotherapy or radiation by enhancing p53 activity .